PubHawk
Lancet Oncol January 2017 PMID 27914822

Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial.

David R Freyer, Lu Chen, Mark D Krailo, Kristin Knight, Doojduen Villaluna, Bonnie Bliss, Brad H Pollock, Jagadeesh Ramdas, Beverly Lange, David Van Hoff, Michele L VanSoelen, John Wiernikowski, Edward A Neuwelt, Lillian Sung

Full text PDF Download social card

Mentions

87
Peak: 2 in May 2017
across 5 sources since May 2017

Extended reach

7,191
potential audience

Total likes

44

Video views

6,552

Mentions per month

May 2017 – Sep 2022

Where it's discussed

  • News78 articles
  • Blogs4 articles
  • YouTube2 videos
  • Reddit2 posts
  • X / Twitter1 posts

AI synopsis

What people are saying

We're still gathering social media discussions on this article. A synopsis appears once there are enough posts to summarize.

AgreementNeither agree nor disagree
InterestNeutral interest
EngagementNeutral engagement
ImpactNeutral impact

Abstract in brief

  • The study investigated whether sodium thiosulfate, administered after cisplatin treatment, can prevent hearing loss in children with cancer, without reducing the drug's effectiveness.
  • It was a multicenter phase 3 trial with children aged 1-18, comparing those who received sodium thiosulfate to a control group that was just observed, measuring hearing loss after treatment.
  • Results showed that sodium thiosulfate significantly reduced the incidence of cisplatin-induced hearing loss, measured through audiometry, without compromising cancer treatment outcomes.]
Read the full abstract

Top posts

Most liked on X and Bluesky
David R. Ghasemi
@DavidRGhasemi1 · X

https://t.co/nULR7aG8mn

Sep 20, 2022 · 2 likes · 639 followers View post →

All mentions

David R. Ghasemi
@DavidRGhasemi1 · X

https://t.co/nULR7aG8mn

Sep 20, 2022 · 2 likes · 639 followers View post →